See more : Swancor Advanced Materials Co., Ltd. (688585.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Seikagaku Corporation (4548.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seikagaku Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Royal Wins Corporation (RYWCF) Income Statement Analysis – Financial Results
- Mobivity Holdings Corp. (MFON) Income Statement Analysis – Financial Results
- Ventura Textiles Limited (VENTURA.BO) Income Statement Analysis – Financial Results
- Varta AG (VAR1.DE) Income Statement Analysis – Financial Results
- Bupa Arabia for Cooperative Insurance Company (8210.SR) Income Statement Analysis – Financial Results
Seikagaku Corporation (4548.T)
About Seikagaku Corporation
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.21B | 33.46B | 34.85B | 27.66B | 28.64B | 28.38B | 30.18B | 29.59B | 30.96B | 29.52B | 29.61B | 26.64B | 27.08B | 27.12B | 27.62B | 27.21B | 27.63B | 24.35B | 23.14B | 22.56B |
| Cost of Revenue | 19.34B | 15.43B | 14.32B | 12.11B | 12.51B | 13.11B | 13.01B | 13.25B | 12.87B | 12.13B | 11.22B | 9.87B | 9.75B | 10.48B | 10.49B | 9.98B | 8.95B | 7.80B | 7.17B | 6.84B |
| Gross Profit | 16.88B | 18.02B | 20.53B | 15.55B | 16.13B | 15.27B | 17.17B | 16.34B | 18.09B | 17.39B | 18.39B | 16.77B | 17.33B | 16.64B | 17.12B | 17.22B | 18.68B | 16.55B | 15.98B | 15.72B |
| Gross Profit Ratio | 46.60% | 53.87% | 58.90% | 56.21% | 56.31% | 53.80% | 56.89% | 55.23% | 58.43% | 58.91% | 62.10% | 62.96% | 64.01% | 61.35% | 62.00% | 63.30% | 67.62% | 67.98% | 69.03% | 69.68% |
| Research & Development | 7.48B | 7.95B | 9.01B | 7.21B | 6.88B | 7.15B | 8.41B | 7.83B | 8.65B | 8.15B | 6.59B | 6.84B | 5.97B | 6.72B | 5.52B | 5.96B | 5.65B | 4.54B | 3.49B | 3.66B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00M | 190.00M | 179.00M | 190.00M | 0.00 | 36.00M | 36.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 606.00M | 1.31B | 1.45B | 1.66B | 1.68B | 1.76B | 1.74B | 1.84B | 1.82B | 1.80B | 1.82B | 1.81B | 1.69B | 1.60B | 1.74B | 1.25B | 1.15B |
| SG&A | 8.96B | 7.96B | 7.03B | 606.00M | 1.31B | 1.45B | 1.66B | 1.68B | 1.76B | 1.74B | 1.84B | 1.82B | 1.80B | 2.01B | 2.00B | 1.86B | 1.79B | 1.74B | 1.29B | 1.19B |
| Other Expenses | 0.00 | 73.00M | 56.00M | 856.00M | 1.89B | 791.00M | 3.39B | 875.00M | 673.00M | 471.00M | 288.00M | 793.00M | 79.00M | 804.00M | 241.00M | 266.00M | 169.00M | 224.00M | 198.00M | 141.00M |
| Operating Expenses | 16.44B | 15.91B | 16.03B | 14.02B | 14.17B | 14.29B | 15.74B | 15.06B | 15.94B | 15.01B | 13.45B | 13.64B | 12.72B | 10.65B | 9.42B | 9.75B | 9.36B | 8.38B | 6.65B | 6.76B |
| Cost & Expenses | 35.78B | 31.34B | 30.35B | 26.13B | 26.68B | 27.40B | 28.75B | 28.30B | 28.82B | 27.14B | 24.67B | 23.51B | 22.46B | 21.13B | 19.92B | 19.73B | 18.31B | 16.18B | 13.82B | 13.60B |
| Interest Income | 150.00M | 51.00M | 28.00M | 61.00M | 131.00M | 109.00M | 62.00M | 59.00M | 77.00M | 88.00M | 123.00M | 162.00M | 201.00M | 221.00M | 238.00M | 251.00M | 263.00M | 230.00M | 159.00M | 106.00M |
| Interest Expense | 4.00M | 5.00M | 11.00M | 16.00M | 18.00M | 22.00M | 27.00M | 31.00M | 36.00M | 17.00M | 21.00M | 32.00M | 40.00M | 48.00M | 55.00M | 61.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.66B | 1.33B | 1.05B | 808.00M | 1.87B | 2.90B | 2.93B | 2.92B | 3.19B | 2.61B | 1.77B | 2.18B | 1.98B | 2.19B | 2.70B | 2.13B | 1.24B | 1.21B | 1.18B | 1.05B |
| EBITDA | 3.36B | 3.44B | 5.55B | 2.34B | -7.65B | 3.88B | 8.28B | 5.43B | 5.34B | 4.99B | 6.71B | 6.51B | 6.71B | 5.41B | 7.87B | 7.05B | 8.11B | 7.29B | 8.73B | 6.78B |
| EBITDA Ratio | 9.27% | 13.15% | 18.43% | 13.80% | 21.02% | 17.87% | 26.98% | 17.99% | 20.42% | 21.42% | 26.08% | 24.79% | 25.49% | 32.62% | 37.89% | 36.83% | 47.79% | 49.48% | 56.09% | 59.95% |
| Operating Income | 433.00M | 2.11B | 4.50B | 1.53B | 1.96B | 977.00M | 1.42B | 1.28B | 2.14B | 2.38B | 4.94B | 3.13B | 4.62B | 3.53B | 5.11B | 4.73B | 6.68B | 5.57B | 6.90B | 6.78B |
| Operating Income Ratio | 1.20% | 6.32% | 12.90% | 5.53% | 6.84% | 3.44% | 4.71% | 4.33% | 6.92% | 8.07% | 16.67% | 11.73% | 17.05% | 13.03% | 18.50% | 17.38% | 24.16% | 22.88% | 29.82% | 30.07% |
| Total Other Income/Expenses | 1.26B | 955.00M | 900.00M | 776.00M | -11.50B | 1.88B | 3.91B | 1.20B | 1.36B | 1.63B | 1.01B | 1.18B | 70.00M | -359.00M | 4.00M | 137.00M | 191.00M | 508.00M | 647.00M | -1.05B |
| Income Before Tax | 1.69B | 3.07B | 5.40B | 3.02B | -9.54B | 2.86B | 5.33B | 2.48B | 3.50B | 4.01B | 5.95B | 4.30B | 4.69B | 3.17B | 5.11B | 4.87B | 6.87B | 6.08B | 7.55B | 5.73B |
| Income Before Tax Ratio | 4.67% | 9.17% | 15.48% | 10.93% | -33.32% | 10.07% | 17.65% | 8.37% | 11.30% | 13.58% | 20.09% | 16.15% | 17.31% | 11.70% | 18.52% | 17.89% | 24.85% | 24.96% | 32.61% | 25.39% |
| Income Tax Expense | -495.00M | 832.00M | 1.66B | -1.24B | 1.30B | 614.00M | 1.40B | 689.00M | 922.00M | 357.00M | 1.20B | 1.05B | 1.42B | 722.00M | 1.54B | 1.69B | 2.62B | 2.54B | 2.87B | 2.10B |
| Net Income | 2.19B | 2.24B | 3.73B | 4.26B | -10.84B | 2.24B | 3.92B | 1.79B | 2.58B | 3.65B | 4.75B | 3.26B | 3.27B | 2.45B | 3.58B | 3.18B | 4.24B | 3.53B | 4.68B | 3.62B |
| Net Income Ratio | 6.04% | 6.68% | 10.71% | 15.41% | -37.84% | 7.91% | 13.00% | 6.04% | 8.33% | 12.36% | 16.02% | 12.22% | 12.07% | 9.04% | 12.94% | 11.67% | 15.36% | 14.51% | 20.21% | 16.06% |
| EPS | 40.07 | 40.48 | 66.31 | 75.53 | -192.14 | 39.75 | 69.29 | 31.55 | 45.39 | 64.27 | 83.55 | 57.33 | 57.58 | 43.16 | 62.94 | 55.68 | 73.67 | 60.93 | 79.24 | 91.40 |
| EPS Diluted | 40.07 | 40.48 | 66.31 | 75.53 | -192.14 | 39.75 | 69.29 | 31.55 | 45.39 | 64.27 | 83.55 | 57.33 | 57.58 | 43.16 | 62.94 | 55.68 | 73.67 | 60.93 | 79.24 | 52.97 |
| Weighted Avg Shares Out | 54.55M | 55.24M | 56.30M | 56.43M | 56.41M | 56.45M | 56.60M | 56.66M | 56.80M | 56.81M | 56.81M | 56.81M | 56.81M | 56.81M | 56.81M | 57.02M | 57.61M | 58.01M | 58.20M | 38.99M |
| Weighted Avg Shares Out (Dil) | 54.55M | 55.24M | 56.30M | 56.43M | 56.41M | 56.45M | 56.60M | 56.66M | 56.80M | 56.81M | 56.81M | 56.81M | 56.81M | 56.81M | 56.81M | 57.02M | 57.61M | 58.01M | 58.20M | 68.42M |
Source: https://incomestatements.info
Category: Stock Reports